Metastatic Breast Cancer

912 clinical trials · Condition

Record	Firm	Date
Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer (NCT01423695)	WiSP Wissenschaftlicher Service Pharma GmbH	2001-02-01
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC (NCT00134680)	Duke University	2000-01-01
Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study (NCT00176046)	Heidelberg University	1999-05-01
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer (NCT00148070)	University of Michigan Rogel Cancer Center	1999-03-01
Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer (NCT05758948)	Hellenic Cooperative Oncology Group	1998-07-05
Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer (NCT00584766)	University of Oklahoma	1987-10-01
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer (NCT00380835)	Celgene Corporation
Companion Pharmacogenetic Study to UMCC 9900/9901 (NCT00146029)	University of Michigan Rogel Cancer Center
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer (NCT03763604)	Eli Lilly and Company
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer (NCT01240928)	Vanderbilt-Ingram Cancer Center
Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer (NCT01134497)	Cardiff University
Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer (NCT02792725)	Eli Lilly and Company

Track Metastatic Breast Cancer automatically

Every clearance here is in the API, with alerts when new ones post.